Pfizer to outsource some drug production, focus on coronavirus vaccine

Topics Pfizer | Coronavirus | Vaccine


Pfizer Inc (PFE.N) said on Friday it is in talks to shift more of its medicine production to outside contractors as it prepares for large-scale production of an experimental vaccine to prevent COVID-19, should it prove safe and effective. The US drugmaker is tapping its network of around 200 outside contractors, which includes Catalent Inc (CTLT.

N), Lonza Group AG (LONN.S), and Thermo Fisher Scientific Inc (TMO.N), to play a bigger role in producing some of its existing medicines, Mike McDermott, president of global supply at Pfizer,.

This article is no longer available in our repository.

There could be multiple reasons for this.